Sanofi Hid MS Drug's Checkered History, Investors Say
Sanofi SA and its top executives allegedly misled investors about the potential success of its subsidiary's multiple sclerosis drug Lemtrada, causing shareholders to miss out on millions of dollars when the...To view the full article, register now.
Already a subscriber? Click here to view full article